Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Gains from Investment Securities (2023 - 2025)

Kura Oncology (KURA) has disclosed Gains from Investment Securities for 3 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 92.14% to $1.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 92.14% decrease, with the full-year FY2025 number at $1.0 million, down 92.14% from a year prior.
  • Gains from Investment Securities was $1.0 million for Q4 2025 at Kura Oncology, up from $969417.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $12.9 million in Q4 2024 to a low of $969417.0 in Q3 2025.
  • A 3-year average of $4.6 million and a median of $1.2 million in 2025 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: rose 25.31% in 2024, then plummeted 92.14% in 2025.
  • Kura Oncology's Gains from Investment Securities stood at $10.3 million in 2023, then rose by 25.31% to $12.9 million in 2024, then tumbled by 92.14% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Gains from Investment Securities are $1.0 million (Q4 2025), $969417.0 (Q3 2025), and $1.2 million (Q2 2025).